Life Sciences

  • Microbiome / Nutrition / Foodtech / Lifestyle
  • Medtech / Connected health / Digital health
  • Biotech & pharmaceuticals
  • Industrial Biotech & Cleantech
  • Animal health / Animal Feed & Nutrition

Read more

Digital Technologies

  • Fintech
  • Retailtech
  • Other digital innovative solutions
  • Hardware & telecom

Read more

Sport & Performance Capital

  • Sport-Health
  • Equipment
  • Food-Nutrition
  • IOT-Digital
  • Sports practice

Read more

Blue Economy

  • Sustainable aquaculture
  • Nutrition Cosmetics Health
  • Industrial Products & Biomaterials
  • Biopolymers and biopackaging
  • Digitalization Blue 3.0
  • Recycling, Bioremediation
  • Climate & Carbon
  • Bioenergies, hydrogen

Read more

News

  • Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
    23 June 2025

    Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

    60% (12/20) complete response rate after treatment with...

  • MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress
    13 June 2025

    MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress

    The Company, a clinical-stage biotechnology company and...

  • Enterome, raises $19 million to fund clinical development of its OncoMimics™ immunotherapies to treat Follicular Lymphoma
    12 June 2025

    Enterome, raises $19 million to fund clinical development of its OncoMimics™ immunotherapies to treat Follicular Lymphoma

    Enterome, a clinical-stage company developing...

    Read more...
  • Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
    2 June 2025

    Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

    Enterome SA, a clinical-stage company developing...

  • Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
    30 May 2025

    Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

    Enterome SA, a clinical-stage company developing...